SINE of CRM1/XPO1, a target of chronic lymphocytic leukemia, could effectively covalently bind cysteine residues in XPO1 cargo binding tank to treat the disease and is being tested in clinical trials targeting a wide range of malignancies [11]. The gene discussed is XPO1; the disease is B-cell chronic lymphocytic leukemia.